Table 1 Baseline characteristics of the study population
Characteristics | Early (n = 52) | Late or never (n = 145) | P-value | Standard difference unweighted | Standard difference weighteda |
|---|---|---|---|---|---|
Age (median, IQR) | 66 (57–79) | 74 (64–83) | 0.015 | -0.3854 | -0.0351 |
Male sex, (n, %) | 34 (65.4) | 91 (62.8) | 0.736 | -0.0866 | -0.1030 |
Years, (n, %) | Â | Â | 0.252 | -0.1896 | -0.0092 |
 Pre-COVID-19 era (2018–2019) | 16 (30.8) | 33 (22.8) |  |  |  |
 Post-COVID-19 era (2020–2022) | 36 (69.2) | 112 (77.2) |  |  |  |
Charlson Comorbidity Index, (median, IQR) | 3 (2–4) | 3 (2–4) | 0.957 | -0.0292 | 0.0416 |
Department in charge, (n, %) | Â | Â | 0.002 | 0.5183 | 0.0124 |
 Medical | 20 (38.5) | 91 (62.8) |  |  |  |
 Surgical | 32 (61.5) | 54 (37.2) |  |  |  |
Time interval between hospital stay and BSI, day (median, IQR) | 21.5 (13.5–35) | 20 (13–34) | 0.501 | 0.1329 | 0.0305 |
Time interval between ICU stay and BSI, day (median, IQR) | 14 (10-24.5) | 14 (8–23) | 0.611 | 0.1018 | 0.0479 |
Time internal between catheter insertion and BSI, day (median, IQR) | 13 (9–18) | 13 (8–21) | 0.708 | 0.0590 | 0.0491 |
Access site of catheter insertion, (n, %) | Â | Â | 0.866 | -0.1233 | 0.0361 |
 Subclavian veinb | 18 (34.6) | 42 (29.0) |  |  |  |
 Internal jugular vein | 8 (15.4) | 23 (15.9) |  |  |  |
 Femoral vein | 11 (21.1) | 39 (26.9) |  |  |  |
 PICC | 15 (28.9) | 41 (28.2) |  |  |  |
Anti-cancer chemotherapy | 4 (7.7) | 17 (11.7) | 0.419 | -0.1326 | -0.0051 |
Steroid or immune-modulator | 19 (36.5) | 63 (43.5) | 0.386 | -0.1317 | -0.1398 |
Total parenteral nutrition | 32 (61.5) | 90 (62.1) | 0.946 | -0.0208 | -0.0546 |
Previous MDRO colonization (n, %) | 30 (57.7) | 94 (64.8) | 0.361 | -0.1178 | -0.0550 |
Quick Pitt bacteremia score, (median, IQR) | 2 (2–3) | 3 (2–3) | 0.026 | -0.3893 | -0.0527 |
Quick SOFA score ≥ 2 (n, %) | 48 (90.4) | 136 (93.8) | 0.412 | -0.1301 | -0.0181 |
LCBI (n, %) | Â | Â | 0.435 | 0.1204 | 0.0894 |
 type 1 | 37 (72.6) | 113 (77.9) |  |  |  |
 type 2 | 15 (27.3) | 32 (22.1) |  |  |  |
BCID panel utilization (n, %) | 15 (28.9) | 38 (26.4) | 0.732 | 0.0669 | -0.0141 |
Number of positive blood culture (n, %) | Â | Â | 0.791 | 0.0739 | 0.0401 |
 One | 19 (36.5) | 56 (38.6) |  |  |  |
 ≥ two | 33 (63.5) | 89 (61.4) |  |  |  |
Pathogen (n, %) | Â | Â | 0.668 | -0.1173 | 0.0364 |
 Gram-negative | 14 (26.9) | 40 (27.6) |  |  |  |
 Gram-positive | 25 (48.1) | 61 (42.1) |  |  |  |
 Candida species | 7 (13.5) | 17 (11.7) |  |  |  |
 Polymicrobial infection | 6 (11.5) | 27 (18.6) |  |  |  |
MDRO infection | 32 (61.5) | 97 (66.9) | 0.486 | -0.1217 | 0.0827 |